Immorta Bio Presents SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting

PR Newswire
May 5, 2025

Immorta Bio was selected to present alongside Pfizer and the University of Pittsburgh at the 2025 American Association of Immunologists Annual Meeting in Honolulu. The company unveiled new data on SenoVax™, its first-in-class senolytic immunotherapy that trains the immune system to target senescent cells—offering a novel approach to treating both cancer and aging.

Read Full Article

Explore More

April 22, 2025

Senescent Cell Removal Unleashes NK Cells Shown to Fight Cancer and Viruses in Animal Models

March 13, 2025

Immorta Bio Presents SenoVax™ Mediated Tumor Remission Data at International Biotechnology Conference

March 11, 2025

Reduction of Chemotherapy Associated Accelerated Aging by ImmortaSome™ Personalized Exosome Rejuvenation

See all news
Get The Latest News and Developments On Our Longevity Journey
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By subscribing, you are acknowledging your consent to receive  Immorta Bio newsletters
19505 Biscayne Blvd, Ste 2350 Aventura, Florida 33180
305 632-2939
info@immortabio.com